Abstract: A semiconductor substrate includes a support substrate, a mask pattern located above the support substrate and including a mask portion, a seed portion locally located in a layer above the support substrate in a plan view, and a semiconductor part including a GaN-based semiconductor and located above the mask pattern to be in contact with the seed portion and the mask portion.

Abstract: The present disclosure provides, for example, a compound represented by the general formula below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt: wherein X1, X2, X3 and X4 are each independently —CR2? or N?, R2 is, for example, a halogen atom, R1 is, for example, —S(?O)2—NH—R8, R8 is, for example, a C1-6 alkyl group, R3 is, for example, a hydrogen atom, R5 is, for example, a halogen atom, R6 is, for example, a hydrogen atom, and R4 is, for example, a cyclopropyl group. The compounds, salts or solvates provided by the present disclosure exhibit high RAF/MEK complex-stabilizing activity and can be used for the treatment or prevention of cell proliferative disorders, particularly cancers.

Abstract: An information processing apparatus according to an embodiment of the present disclosure processes information about a position of an object moved by a mobile object, and includes an output unit configured to output the information about the position of the object. The information about the position of the object is obtained based on holding information indicating whether the object is held or not held by the mobile object and information about a position of the mobile object. The information about the position of the mobile object is obtained based on a captured image captured by an imaging device.

Abstract: The present disclosure provides, for example, a compound represented by general formula (6) below or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate of the compound or salt: wherein X1, X2, X3 and X4 are each independently —CR2? or —N?, R2 is, for example, a halogen atom, R1 is, for example, —S(?O)2—NH—R8, R8 is, for example, a C1-6 alkyl group, R3 is, for example, a hydrogen atom, R5 is, for example, a halogen atom, R6 is, for example, a hydrogen atom, and R4 is, for example, a cyclopropyl group. The compounds, salts or solvates provided by the present disclosure exhibit high RAF/MEK complex-stabilizing activity and can be used for the treatment or prevention of cell proliferative disorders, particularly cancers.

Abstract: An objective of the present invention is to provide low-molecular-weight compounds that can inhibit Src family kinases. The present invention relates to compounds represented by general formula (I) or pharmacologically acceptable salts thereof. In the formula, Ar1 is optionally substituted C6-10 arylene or 5- to 10-membered heteroarylene, and Ar2 is optionally substituted C6-10 aryl or 5- to 10-membered heteroaryl. R1 and R2 are defined as described in the specification.

Abstract: An objective of the present invention is to provide low-molecular-weight compounds that can inhibit Src family kinases. The present invention relates to compounds represented by general formula (I) or pharmacologically acceptable salts thereof. In the formula, Ar1 is optionally substituted C6-10 arylene or 5- to 10-membered heteroarylene, and Ar2 is optionally substituted C6-10 aryl or 5- to 10-membered heteroaryl. R1 and R2 are defined as described in the specification.

Abstract: The present invention provides a p27 protein inducing agent comprising a compound represented by general formula (11) below or pharmaceutically acceptable salt thereof as an active ingredient: wherein G1, G2, G3 and G8 are each independently selected from —N? etc., Ring G6 is selected from divalent aryl etc., A is selected from amino etc., G4 is selected from oxygen etc., G5 is selected from oxygen etc., G7 is selected from —CH2— etc., and R2 is selected from C1-6 alkyl etc.

Abstract: The present invention provides a compound represented by general formula (1) below or a pharmaceutically acceptable salt thereof: wherein: X is selected from heteroaryl etc., Y1 and Y2 are selected from —N? etc., Y3 and Y4 are selected from —CH? etc., A is selected from sulfamide etc., R1 is selected from hydrogen etc., and R2 is selected from C1-6 alkyl etc. The compound or salt has sufficiently high antitumor activity, and is useful in the treatment of cell proliferative disorders, particularly cancers. The present invention also provides a pharmaceutical composition containing the compound or salt as an active ingredient.

Abstract: The present invention provides a compound represented by general formula (1) below or a pharmaceutically acceptable salt thereof: wherein: X is selected from heteroaryl etc., Y1 and Y2 are selected from —N? etc., Y3 and Y4 are selected from —CH? etc., A is selected from sulfamide etc., R1 is selected from hydrogen etc., and R2 is selected from C1-6 alkyl etc. The compound or salt has sufficiently high antitumor activity, and is useful in the treatment of cell proliferative disorders, particularly cancers. The present invention also provides a pharmaceutical composition containing the compound or salt as an active ingredient.

Abstract: The present invention provides a compound represented by general formula (1) below or a pharmaceutically acceptable salt thereof: wherein: X is selected from heteroaryl etc., Y1 and Y2 are selected from —N? etc., Y3 and Y4 are selected from —CH? etc., A is selected from sulfamide etc., R1 is selected from hydrogen etc., and R2 is selected from C1-6 alkyl etc. The compound or salt has sufficiently high antitumor activity, and is useful in the treatment of cell proliferative disorders, particularly cancers. The present invention also provides a pharmaceutical composition containing the compound or salt as an active ingredient.

Abstract: The present invention provides a p27 protein inducing agent comprising a compound represented by general formula (11) below or pharmaceutically acceptable salt thereof as an active ingredient: wherein G1, G2, G3 and G8 are each independently selected from —N? etc., Ring G6 is selected from divalent aryl etc., A is selected from amino etc., G4 is selected from oxygen etc., G5 is selected from oxygen etc., G7 is selected from —CH2— etc., and R2 is selected from C1-6 alkyl etc.

Abstract: The present invention provides a compound represented by general formula (1) below or a pharmaceutically acceptable salt thereof: wherein: X is selected from heteroaryl etc., Y1 and Y2 are selected from —N? etc., Y3 and Y4 are selected from —CH? etc., A is selected from sulfamide etc., R1 is selected from hydrogen etc., and R2 is selected from C1-6 alkyl etc. The compound or salt has sufficiently high antitumor activity, and is useful in the treatment of cell proliferative disorders, particularly cancers. The present invention also provides a pharmaceutical composition containing the compound or salt as an active ingredient.

Abstract: A liquid crystal display device includes a first substrate having a plurality of first electrodes, a second substrate facing the first substrate and having a plurality of second electrodes perpendicular to the first electrodes to define sub-pixels at intersection regions between the first and second electrodes, a liquid crystal layer between the first and second substrates, a plurality of color filters between the first and second substrates adapted to correspond to respective sub-pixels, the color filters including first color filters and second color filters having a different shape than the first color filters, a black matrix between the color filters, the black matrix including vertical portions, horizontal portions, and step portions, each of the step portions corresponding to a respective second color filter, and a plurality of patterned spacers between the first and second substrates, each of the patterned spacers overlaps with a respective step-portion of the black matrix.

Abstract: A display cell is mounted on a color-compensating cell. The display cell has a pair of substrates each having an alignment-treated surface, a first liquid-crystal layer and electrodes. Multiplex drive signals are supplied to the electrodes. The color-compensating cell has a second liquid-crystal layer. The molecules of the first liquid-crystal layer are twisted by a twist angle ranging from 160.degree. to 270.degree.. The molecules of the second liquid-crystal layer are twisted by the same angle in the opposite direction. The substrates are alignment-treated in two directions, respectively, which are substantially at right angles to each other. One of the polarizing plates has an optical axis crossing at 35.degree. to 50.degree. with an aligning direction of the liquid crystal molecules on that substrate adjacent to the polarizing plate, and crossing with the optical axis of the other polarizing plate at right angles.

Abstract: A method of manufacturing color filters in which a photosensitive film, which is used for forming filter elements, is formed on a substrate. A photomask with a given stripe pattern is placed above the photoresistive film. Under this condition, the photomasked-film is subjected to a first exposure process. The photomask is then moved in the direction of the stripes in the mask pattern. Following a second exposure process, developing, dyeing and dyeing-preventing processes are performed for color filter element formation. The foregoing steps are performed for each filter element for a specified color.

Abstract: A projection display apparatus includes a light source unit for generating light for image formation, an electro-optical display device for displaying an optical image by utilizing the light emitted from the light source unit, and an enlarging/projection lens. The light source unit, the display device, and the projection lens are accommodated in a housing with vent openings. The housing also includes a fan for cooling the interior of the housing with cool air and a cooler for maintaining a display panel within a predetermined temperature range. The light source unit includes a lamp and a reflector and is designed not to cause image deformation and formation of a shadow of a discharge portion. In order to display a television image on the display device, all television image display circuit units excluding an antenna are accommodated in the housing. The enlarging/projection lens can control a magnification and a focal point of the image projected on the screen.

Abstract: Stabilizer compositions for halogen-containing polymers are provided composed of a .beta.-diketone as well as metal and organotin enolate salts thereof; and a hydrotalcite having the general formula:Mg.sub.1-x Al.sub.x (OH).sub.2 A.sub.x/2.mH.sub.2 Owhereinx is a number from 0 to 0.5;A is CO.sub.3.sup.= or SO.sub.4.sup.=, andm is a number representing the number of H.sub.2 O in the molecule.The stabilizer compositions are effective in enhancing the resistance to deterioration by heat and light of halogen-containing polymers and especially polyvinyl halide resins. The .beta.-diketone and hydrotalcite in these compositions exhibit a synergistic stabilizing effectiveness superior to either alone in like amount.